Intravenous Immunoglobulin Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025

Oct 2018| TMR956A| Transparency

Report Highlights

Global Intravenous Immunoglobulin Market: Scope and Methodology

This report analyzes the current and future prospects of the global intravenous immunoglobulin market. It comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments. The report is a combination of primary and secondary research. Primary research formed the bulk of the research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2016 to 2026, considering the macro and micro environmental factors. Growth rates for each segment within the global intravenous immunoglobulin market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market and future opportunities has been provided in the overview section. This section of the report also provides insights into the key trends of the intravenous immunoglobulin market such as shift from intravenous to subcutaneous infusion of immunoglobulin. The key indicators influencing the global intravenous immunoglobulin market taken into consideration include prevalence of immunological disorders, global blood and plasma yield, and geriatric population. The report also includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global intravenous immunoglobulin market. The report also highlights key events of the global intravenous immunoglobulin industry. A value chain analysis along with list of major players, hospitals, and distributors is also included in the report.

Market revenue in terms of US$ Mn for the period between 2016 and 2026 along with the compound annual growth rate (CAGR %) from 2018 to 2026 are provided for all the segments, considering 2017 as the base year. The year-on-year growth of the global intravenous immunoglobulin market for each segment is also reflected. Additionally, market related factors such as increase in preference for product innovation and rise in the number of acute and chronic patients in various regions and historical year-on-year growth have been taken into consideration while estimating the market size.

Global Intravenous Immunoglobulin Market: Segmentation

Based on indication, the global intravenous immunoglobulin market has been segmented into chronic inflammatory demyelinating polyneuropathy (CIDP), primary humoral immunodeficiency, idiopathic thrombocytopenic purpura (ITP), Guillain-Barre syndrome, myasthenia gravis, multifocal motor neuropathy (MMN), Kawasaki disease, hypogammaglobulinemia, chronic lymphocytic leukemia, and others. In terms of end-user, the global market has been segmented into hospitals, clinics, and home care. The hospitals segment is projected to dominate the market during the forecast period. However, the home care segment is expected to expand at the highest CAGR during the forecast period.

Geographically, the global intravenous immunoglobulin market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Additionally, the regions have been divided into major countries/sub-regions. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Japan, India, Australia, Brazil, and Mexico.

Global Intravenous immunoglobulin Market: Competitive Landscape

The report also profiles major players in the global intravenous immunoglobulin market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. A thorough market share analysis of major companies operating in the global intravenous immunoglobulin market is provided in the report. The report also includes a competition matrix that provides insights into recent developments and activities undertaken by the major players. Key companies profiled in the report include Shire plc, ADMA Biologics, Inc., China Biologic Products, Inc., CSL Behring LLC, Grifols S.A., Kedrion S.p.A., LFB Biomedicaments S.A., Octapharma AG, and Sanquin Plasma Products B.V.

The global intravenous immunoglobulin market has been segmented as follows:

Global Intravenous immunoglobulin Market, by Indication
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Primary Humoral Immunodeficiency
Idiopathic Thrombocytopenic Purpura (ITP)
Guillain-Barre Syndrome
Myasthenia Gravis
Multifocal Motor Neuropathy (MMN)
Kawasaki Disease
Hypogammaglobulinemia
Chronic Lymphocytic Leukemia
Others

Global Intravenous Immunoglobulin Market, by End-user
Hospitals
Clinics
Home Care

Global Intravenous Immunoglobulin Market, by Region
North America
U.S.
Canada
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
Asia Pacific
Australia & New Zealand
Japan
China
India
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East & Africa

  • Table 1 : Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
  • Table 2 : Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
  • Table 3 : Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Region, 2018–2026
  • Table 4 : North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
  • Table 5 : North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
  • Table 6 : North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2018–2026
  • Table 7 : U.S. Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
  • Table 8 : U.S. Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
  • Table 9 : Canada Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
  • Table 10 : Canada Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
  • Table 11 : Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
  • Table 12 : Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
  • Table 13 : Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2018–2026
  • Table 14 : U.K. Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
  • Table 15 : U.K. Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
  • Table 16 : Germany Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
  • Table 17 : Germany Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
  • Table 18 : France Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
  • Table 19 : France Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
  • Table 20 : Spain Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
  • Table 21 : Spain Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
  • Table 22 : Italy Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
  • Table 23 : Italy Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
  • Table 24 : Rest of Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
  • Table 25 : Rest of Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
  • Table 26 : Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
  • Table 27 : Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
  • Table 28 : Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2018–2026
  • Table 29 : China Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
  • Table 30 : China Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
  • Table 31 : Japan Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
  • Table 32 : Japan Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
  • Table 33 : India Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
  • Table 34 : India Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
  • Table 35 : Australia & New Zealand Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
  • Table 36 : Australia & New Zealand Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
  • Table 37 : Rest of Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
  • Table 38 : Rest of Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
  • Table 39 : Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2016–2026
  • Table 40 : Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016–2026
  • Table 41 : Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2016–2026
  • Table 42 : Brazil Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
  • Table 43 : Brazil Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
  • Table 44 : Mexico Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
  • Table 45 : Mexico Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
  • Table 46 : Rest of Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
  • Table 47 : Rest of Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
  • Table 48 : Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication Type, 2016–2026
  • Table 49 : Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016–2026
  • Table 50 : Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2016–2026
  • Table 51 : GCC Countries Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
  • Table 52 : GCC Countries Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
  • Table 53 : South Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
  • Table 54 : South Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
  • Table 55 : Rest of Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
  • Table 56 : Rest of Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
  • Figure 1 : Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2016–2026
  • Figure 2 : Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Indication, 2018 and 2026
  • Figure 3 : Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenue, US$ Mn, 2016–2026
  • Figure 4 : Global Primary Humoral Immunodeficiency Market Revenue, US$ Mn, 2016–2026
  • Figure 5 : Global Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, US$ Mn, 2016–2026
  • Figure 6 : Global Guillain-Barre Syndrome Market Revenue, US$ Mn, 2016–2026
  • Figure 7 : Global Myasthenia Gravis Market Revenue, US$ Mn, 2016–2026
  • Figure 8 : Global Multifocal Motor Neuropathy (MMN) Market Revenue, US$ Mn, 2016–2026
  • Figure 9 : Global Kawasaki Disease Market Revenue, US$ Mn, 2016–2026
  • Figure 10 : Global Hypogammaglobulinemia Market Revenue, US$ Mn, 2016–2026
  • Figure 11 : Global Chronic Lymphocytic Leukemia Market Revenue, US$ Mn, 2016–2026
  • Figure 12 : Global Other Indications Market Revenue, US$ Mn, 2016–2026
  • Figure 13 : Intravenous Immunoglobulin (IVIG) Market Attractiveness Analysis, by Indication
  • Figure 14 : Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by End-user, 2018 and 2026
  • Figure 15 : Global Hospitals Market Revenue, US$ Mn,
  • Figure 16 : Global Clinics Market Revenue, US$ Mn,
  • Figure 17 : Global home care Market Revenue, US$ Mn, 2016–2026
  • Figure 18 : Intravenous Immunoglobulin (IVIG) Market Attractiveness Analysis, by End-user
  • Figure 19 : Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Region, 2018 and 2026
  • Figure 20 : Intravenous Immunoglobulin (IVIG) Market Attractiveness Analysis, by Region
  • Figure 21 : North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2018–2026
  • Figure 22 : North America Market Attractiveness Analysis, by Country
  • Figure 23 : North America Market Value Share Analysis, by Indication, 2018 and 2026
  • Figure 24 : North America Market Value Share Analysis, by End-user, 2018 and 2026
  • Figure 25 : North America Market Value Share Analysis, by Country, 2018 and 2026
  • Figure 26 : North America Market Attractiveness Analysis, by Indication
  • Figure 27 : North America Market Attractiveness Analysis, by End-user
  • Figure 28 : Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2018–2026
  • Figure 29 : Europe Market Attractiveness Analysis, by Country/Sub-region
  • Figure 30 : Europe Market Value Share Analysis, by Indication, 2018 and 2026
  • Figure 31 : Europe Market Value Share Analysis, by End-user, 2018 and 2026
  • Figure 32 : Europe Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
  • Figure 33 : Europe Market Attractiveness Analysis, by Indication
  • Figure 34 : Europe Market Attractiveness Analysis, by End-user
  • Figure 35 : Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2016–2026
  • Figure 36 : Asia Pacific Market Attractiveness Analysis, by Country/Sub-region
  • Figure 37 : Asia Pacific Market Value Share Analysis, by Indication, 2018 and 2026
  • Figure 38 : Asia Pacific Market Value Share Analysis, by End-user, 2018 and 2026
  • Figure 39 : Asia Pacific Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
  • Figure 40 : Asia Pacific Market Attractiveness Analysis, by Indication
  • Figure 41 : Asia Pacific Market Attractiveness Analysis, by End-user
  • Figure 42 : Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2016–2026
  • Figure 43 : Latin America Market Attractiveness Analysis, by Country/Sub-region
  • Figure 44 : Latin America Market Value Share Analysis, by Indication, 2018 and 2026
  • Figure 45 : Latin America Market Value Share Analysis, by End-user, 2018 and 2026
  • Figure 46 : Latin America Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
  • Figure 47 : Latin America Market Attractiveness Analysis, by Indication
  • Figure 48 : Latin America Market Attractiveness Analysis, by End-user
  • Figure 49 : Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2016–2026
  • Figure 50 : Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region
  • Figure 51 : Middle East & Africa Market Value Share Analysis, by Indication, 2018 and 2026
  • Figure 52 : Middle East & Africa Market Value Share Analysis, by End-user, 2018 and 2026
  • Figure 53 : Middle East & Africa Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
  • Figure 54 : Middle East & Africa Market Attractiveness Analysis, by Indication
  • Figure 55 : Middle East & Africa Market Attractiveness Analysis, by End-user
  • Figure 56 : Global Intravenous Immunoglobulin (IVIG) Market Share Analysis, by Company (2017)

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report